You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

TERIPARATIDE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for teriparatide and what is the scope of freedom to operate?

Teriparatide is the generic ingredient in four branded drugs marketed by Alvogen, Lilly, Almaject, Apotex, Teva Pharms Usa, and Sanofi Aventis Us, and is included in six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Teriparatide has thirty-seven patent family members in twenty-five countries.

There are four drug master file entries for teriparatide. Five suppliers are listed for this compound.

Summary for TERIPARATIDE
International Patents:37
US Patents:1
Tradenames:4
Applicants:6
NDAs:6
Drug Master File Entries: 4
Finished Product Suppliers / Packagers: 5
Raw Ingredient (Bulk) Api Vendors: 28
Clinical Trials: 151
Drug Prices: Drug price trends for TERIPARATIDE
What excipients (inactive ingredients) are in TERIPARATIDE?TERIPARATIDE excipients list
DailyMed Link:TERIPARATIDE at DailyMed
Drug Prices for TERIPARATIDE

See drug prices for TERIPARATIDE

Recent Clinical Trials for TERIPARATIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universidade Federal FluminensePhase 4
Universidad de ValparaisoPhase 4
Peking Union Medical College HospitalN/A

See all TERIPARATIDE clinical trials

Pharmacology for TERIPARATIDE
Paragraph IV (Patent) Challenges for TERIPARATIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FORTEO Injection teriparatide 250 mcg/mL, 2.4 mL prefilled Pen 021318 1 2015-07-27

US Patents and Regulatory Information for TERIPARATIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-002 Jun 25, 2008 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharms Usa TERIPARATIDE teriparatide SOLUTION;SUBCUTANEOUS 208569-001 Nov 16, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Almaject TERIPARATIDE teriparatide SOLUTION;SUBCUTANEOUS 218771-001 Jun 4, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TERIPARATIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-001 Nov 26, 2002 ⤷  Sign Up ⤷  Sign Up
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-002 Jun 25, 2008 ⤷  Sign Up ⤷  Sign Up
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-001 Nov 26, 2002 ⤷  Sign Up ⤷  Sign Up
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-001 Nov 26, 2002 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for TERIPARATIDE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
STADA Arzneimittel AG Movymia teriparatide EMEA/H/C/004368
Movymia is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Authorised no yes no 2017-01-11
Eli Lilly Nederland B.V. Forsteo teriparatide EMEA/H/C/000425
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Authorised no no no 2003-06-10
Gedeon Richter Plc. Terrosa teriparatide EMEA/H/C/003916
Terrosa is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Authorised no yes no 2017-01-04
EuroGenerics Holdings B.V. Qutavina teriparatide EMEA/H/C/005388
Qutavina is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Withdrawn no yes no 2020-08-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for TERIPARATIDE

Country Patent Number Title Estimated Expiration
Japan 2007530241 ⤷  Sign Up
Hungary E045180 ⤷  Sign Up
Australia 2005231731 Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose ⤷  Sign Up
Eurasian Patent Organization 200601801 УСТРОЙСТВО ДЛЯ ДОЗИРОВАНИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ С ПРУЖИННЫМ БЛОКИРУЮЩИМ УСТРОЙСТВОМ, ПРИВОДИМЫМ В ДЕЙСТВИЕ ПРИ ВВЕДЕНИИ ПОСЛЕДНЕЙ ДОЗЫ ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.